What Is VLDL Cholesterol? Normal vs Optimal Range Explained

Most lipid panels focus on LDL and total cholesterol, relegating VLDL to an afterthought—yet VLDL remnants are independently atherogenic and may drive cardiovascular risk more directly than LDL in metabolically unhealthy patients. Labs flag VLDL only above 40 mg/dL, but liver overproduction of triglyceride-rich particles begins well before that threshold. The CTD catalogs over 520 chemical-gene interactions involving apolipoprotein B (APOB) and microsomal triglyceride transfer protein (MTTP)—the two genes most critical for VLDL assembly and secretion. VLDL is usually estimated as fasting triglycerides divided by 5, so an optimal VLDL of 5–25 mg/dL corresponds to triglycerides of 25–125 mg/dL. When VLDL exceeds 25 mg/dL, the liver is packaging more triglycerides into lipoproteins than tissues can clear, leaving remnant particles circulating in the bloodstream where they penetrate arterial walls and drive plaque formation.

PubMed indexes over 22,000 publications on VLDL metabolism and its role in cardiovascular disease. The critical metabolic insight is that VLDL overproduction is primarily driven by insulin resistance and excess carbohydrate intake—not by dietary fat. When cells become insulin-resistant, glucose disposal slows, and the liver converts excess glucose into triglycerides via de novo lipogenesis, packaging them into VLDL for export. This explains why reducing refined carbohydrates and sugar lowers VLDL more effectively than reducing dietary fat. FAERS documents over 5,600 adverse metabolic events associated with atypical antipsychotics (olanzapine, quetiapine, clozapine), which cause insulin resistance and metabolic syndrome that dramatically elevates VLDL production. Corticosteroids and estrogen-containing oral contraceptives also stimulate hepatic VLDL output through distinct mechanisms.

After VLDL delivers its triglyceride cargo to muscle and fat tissue, the depleted particle becomes an IDL (intermediate-density lipoprotein) remnant, which either returns to the liver or further loses triglycerides to become LDL. These VLDL remnants are cholesterol-enriched and small enough to penetrate the arterial wall, where they trigger inflammatory responses and foam cell formation. Recent genetic studies using Mendelian randomization have confirmed that triglyceride-rich lipoprotein remnants (primarily from VLDL) are causally linked to coronary artery disease independent of LDL cholesterol levels. This means that a patient with optimal LDL but elevated VLDL still carries significant cardiovascular risk—a scenario that standard lipid panels may not adequately flag when only LDL is examined in isolation.